| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21cfb7dd79973529725cde19b4f43cba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 |
| filingDate |
2010-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9bd42f84da54c249f1f71092db75be0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b25339a1f323cd5adb820845f5121072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_197d544374ced95623a2eec29e5c5a19 |
| publicationDate |
2016-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-022862-B1 |
| titleOfInvention |
USE OF BENZIDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES |
| abstract |
The present invention relates to the use of benzydamine or its physiologically acceptable acid addition salts in the preparation of a medicament or pharmaceutical composition for the treatment of inflammatory diseases caused by the expression of the p40 cytokine subunit, where the inflammatory disease is selected from the group consisting of psoriatic arthritis and psoriasis. The drug and pharmaceutical composition is intended for local or systemic administration. The present invention also relates to a method of treating said diseases, comprising administering to a patient in need thereof a therapeutically effective amount of benzydamine or its physiologically acceptable acid addition salts, where the administration may be local or systemic. |
| priorityDate |
2009-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |